OneSkin

AI to quantify senescent cell counts

Latest articles

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...
OneSkin

A long-awaited AI approach can now be implemented in screening for anti-senescence drug candidates.

Developing a novel therapeutic drug can cost between $161 million and $2 billion. It can take 12 long years from lead identification and through clinical trials. Even so, only 5 in 5000 drugs make it to the market [1].

Longevity.Technology: Artificial intelligence (AI) has been booming within the pharmaceutical sector over the past five years. In fact, Business Insider has found that AI can curb up to 70% of drug development costs [2]. While pharma has taken a long time to adopt a more digital approach, the benefits have become too obvious to ignore and investments into AI have increased in all fields. The Longevity sector is no different.

Professor Shinsuke Yuasa from the Keio University School of Medicine in Tokyo has been focusing on AI development for drug development in Longevity. There are many approaches to machine learning but this research group focuses on convolutional neural networks (CNN) – deep neural networks commonly applied for visual imagery analysis that expresses how one shape is modified by another.

A CNN approach has already allowed for endothelial cell identification derived from pluripotent stem cells, using phase-contrast microscopy images [3]. However, their most recent – and possibly most exciting – breakthrough is the development of DeepSeSMo.

So what is DeepSeSMo? It is a CNN based scoring system that was trained to quantify the number of senescent cells based on biological microscopy slides. Senescent cells are cells that have an arrested cell cycle found during aging. They have distinct morphologies with enlarged and flat cell bodies and distinct aggregation heterochromatin, a tightly-packed form of DNA.

Healthy cells were triggered into senescence through three different stressors associated with senescence: reactive oxygen species via H2O2 exposure, the anti-cancer reagent camptothecin and replication stress through repetitive passage of cells.

Three stressors were explored to determine if the mechanisms that triggered cells into a senescence affected the developed algorithm. It was no surprise that when the algorithm was trained on a combined set of senescent cells from all three stressors, it gave more generalisable and accurate results.

The training set consisted of human umbilical vein endothelial cells and the evaluation of just how well the algorithm was trained was done on human diploid fibroblasts. Not only did the results accurately predict the quantity of senescent cells, but it did so at an impressive 0.08-0.1ms.

Once validated, this algorithm was tested on tissue treated with various drugs in an attempt to find senolytic or senotherapeutic drugs – ones removing senescent cells or ones preventing cells from entering the senescence phase. Indeed, four targets were identified: terreic acid, PD-98059, daidzein and Y-27632·2HCl [4].

Longevity properties have been identified for all of the drugs picked out by the algorithm. Terreic acid extends yeast’s lifespan [5], PD-98059 and daizein suppresses cellular senescence and associated phenotypes [6] [7] and Y-27632·2HCl regulates the cell cycle more generally [8].

 


 

Deep-SeSMo is likely to be the beginning of the machine-learning boom within aging research for both research and industry, cutting down costs and saving lives…

 


 

All results were cross validated and confirmed with the accepted biological quantification of senescence using senescence-associated beta galactoside. Even so the authors point out the possible limitations. Cells in the intermediate state transitioning into senescence lead to false negatives or positives, yet within this specific study this did not change results when accounted for [4].

Such an approach could be used to eliminate the human bias and error in biological methods and applied on a large scale. Senolytic drugs could be screened at a faster and cheaper rate leading to the development of only the best candidates in the pipeline.

Furthermore, this particular algorithm could further Longevity research though elucidation of senescent mechanisms. Deep-SeSMo picks up characteristics unique to senescent cells and can thus be trained further to identify how and when they arise, as well as exploring the senescence threshold.

Deep-SeSMo is likely to be the beginning of the machine-learning boom within aging research for both research and industry, cutting down costs and saving lives.

 

[1] https://www.medicinenet.com/script/main/art.asp?articlekey=9877
[2] https://tinyurl.com/y22w8pcj
[3] https://pubmed.ncbi.nlm.nih.gov/29754958/
[4] https://www.nature.com/articles/s41467-020-20213-0
[5] https://tinyurl.com/y5bqfyy9
[6] https://www.nature.com/articles/onc2013477
[7] https://www.mdpi.com/1422-0067/15/11/21419
[8] https://www.sciencedirect.com/science/article/pii/S0003996915000680?via%3Dihub

 

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
OneSkin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

NAD+ and metformin: AgelessRx’s anti-aging platform

Personalised longevity medicine is the top goal for AgelessRx. In November we spoke to Anar Isman, the Co-founder & CEO of AgelessRx, about PEARL, the...
Apollo Neuro

Related articles

Plastic surgery in-a-box: a cryo biotech innovation

Future-facing Uvence is innovating for the future of your face. The biotech market is growing, as coverage on Longevity.Technology evidences. The ripples of biotech innovation...

AgeX and LyGenesis to negotiate merger agreement

The biotech merger between AgeX and LyGenesis will neaten-up Juvenescence's portfolio. AgeX Therapeutics, a biotech developing therapeutics for human aging and cell regeneration, and LyGenesis,...

Rejuvenate Biomed bags €3.2m for healthy aging R&D

Belgium biotech secures €3.2m Series A to advance the development of healthy aging products. Rejuvenate Biomed, which is based in Antwerp, has announced it has...

OneSkin: turning back time for your skin

Skin rejuvenating cream goes more than skin deep with senotherapeutic treatment. Last year we reported on the launch of OneSkin, a topical senotherapeutic skin treatment...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...
OneSkin